Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Indevus CEO Glenn Cooper: the acquisition 'firmly establishes Indevus as an emerging leader in the specialty areas of urology and men's health'; transaction…
Indevus CEO Cooper: the deal 'takes two very good, but relatively small specialty biopharmaceutical companies and creates out of the box a larger, stronger and…
Indevus and Valera completed the merger on April 18, 2007 following stockholder approval, formally combining Vantas and Sanctura under one urology-focused…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Urology/endocrinology; stock deal; Vantas (histrelin) and Supprelin
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Indevus Pharmaceuticals, Inc. / Valera Pharmaceuticals Inc. (this deal) | 2006 | $120M | — |
| Indevus Pharmaceuticals, Inc. / Schering AG | 2005 | $30M | — |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Crucell N.V. / Berna Biotech AG | 2006 | $450M | 85 |
| Lonza Group AG / Cambrex Bioproducts and Biopharma businesses | 2006 | $460M | 83 |
| Reckitt Benckiser plc / Boots Healthcare International | 2006 | $3.4B | 82 |
| Genentech, Inc. (Roche Group) / Tanox Inc. | 2006 | $919M | 80 |
← Browse all deals · How we score deals
More: 2006 deals